Imipenem+Cilastatin/Relebactam

ApprovedSmall molecule

Imipenem+Cilastatin/Relebactam is one of 107 small molecule programs targeting Bacterial Pneumonia. It is currently in Approved.

Indications

Total Trials

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial PneumoniaActive, not recruiting

Cystic FibrosisActive, not recruiting

Urinary Tract InfectionActive, not recruiting

Bacterial PneumoniaPhase 3

Active, not recruiting

Cystic FibrosisApproved

Active, not recruiting

Urinary Tract InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Imipenem+Cilastatin/Relebactam

Merck & Co.

Approved

1 2

Onglyza

AstraZeneca

Preclinical

2 3

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 5

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 6

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Aztreonam Lysine

Gilead

Preclinical

5 8

Capromorelin

UUniversity of Aarhus

Preclinical

1 9

Advil

KKenvue Brands

Preclinical

1 10

Tums

Otsuka

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Urinary Tract Infection1 trial

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03293485·83 enrolled

Cystic Fibrosis1 trial

Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

Terminated·HHartford Hospital·Phase 4·NCT05561764·4 enrolled

Bacterial Pneumonia1 trial

Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

Completed·EEvopoint Biosciences Inc.·Phase 3·NCT05204563·450 enrolled

Bacterial Infection1 trial

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02452047·50 enrolled

Prospective1 trial

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT04983901·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Imipenem+Cilastatin/Relebactam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Imipenem+Cilastatin/Relebactam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Imipenem+Cilastatin/Relebactam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Imipenem+Cilastatin/Relebactam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Urinary Tract Infection1 trial

Cystic Fibrosis1 trial

Bacterial Pneumonia1 trial

Bacterial Infection1 trial

Prospective1 trial

References

Drug Info

Quick Facts

Related News